Lohith Gowda, MD, MRCP
Associate Professor of Internal Medicine (Medical Oncology & Hematology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Assistant Professor of Medicine (Hematology), Internal Medicine
About
Copy Link
Titles
Associate Professor of Internal Medicine (Medical Oncology & Hematology)
Assistant Professor of Medicine (Hematology), Internal Medicine
Biography
Curing hematologic cancers with precision medicine and minimal toxicity has been a multigeneration challenge and a highly prioritized work for our group at Yale. Through continual engagement with patients and their families, educational meetings and well informed decision making sessions, we help our patients navigate the field of transplantation and cellular therapy. Our multidisciplinary team while trying to harness the curative promise of cellular immunotherapy also has special focus to enhance its safety and provide long term supervision for cancer survivors. We strongly encourage our patients to learn the strengths and limitations of the existing standard of care, the knowledge of which could be applied to personalize treatment plans and foster research environment to advance the broader field.
Last Updated on April 07, 2025.
Appointments
Medical Oncology and Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
- Yale Center for Immuno-Oncology
- Yale CTAP
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Advanced Fellowship
- MD Anderson Cancer Center (2017)
- Advanced Fellowship
- NY Presbyterian Cornell/New York Blood Center (2016)
- Fellowship
- Albert Einstein College of Medicine (2014)
- Internship/Residency
- Drexel University College of Medicine (2011)
- General Medicine Trainee
- National Health Service UK (2008)
- MD
- Rajiv Gandhi University (2004)
Research
Copy Link
Overview
Targeted therapy; Transfusion Associated Immunomodulation, Immunotherapy, Cellular Therapy, Regenerative Medicine
Medical Research Interests
Anemia, Aplastic; Blood Transfusion; Bone Marrow Diseases; Hematopoietic Stem Cell Transplantation; Immunotherapy; Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis
ORCID
0009-0001-1726-9749
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lohith Gowda's published research.
Publications Timeline
A big-picture view of Lohith Gowda's research output by year.
Research Interests
Research topics Lohith Gowda is interested in exploring.
Stuart Seropian, MD
Nikolai Podoltsev, MD, PhD
Francine Foss, MD
Jan Philipp Bewersdorf, MD, FACP
Alexa Siddon, MD
Iris Isufi, MD
71Publications
1,026Citations
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Multiple Myeloma
Blood Transfusion
Primary Myelofibrosis
Leukemia
Publications
2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Hansen D, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja J, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal M, Gowda L, Hashmi H, Mirza A, Mohan M, Narra R, Rosko A, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini M, Akhtar O, Sidana S, Patel K. Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. Blood Cancer Journal 2026, 16: 80. PMID: 41980929, PMCID: PMC13194909, DOI: 10.1038/s41408-026-01496-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRelapsed/Refractory Multiple MyelomaImmune effector cell-associated neurotoxicity syndromeStandard-of-careCiltacabtagene autoleucelResponse rateMultiple myelomaCenter for International Blood and Marrow Transplant Research registryAnti-B-cell maturation antigenChimeric antigen receptor T cellsEfficacy of ciltacabtagene autoleucelRelapsed/refractory multiple myeloma patientsComplete response ratePartial response rateTreatment-related mortalityCranial nerve palsyCytokine release syndromeMedian Follow-UpPatients to dateCranial nerves VIIProgression-FreeExtramedullary diseaseOverall survivalMaturation antigenAdvanced diseaseMedian ageMalignant Hematological Diseases: Hyperleukocytosis
Gowda L, Hosing C. Malignant Hematological Diseases: Hyperleukocytosis. 2026, 1-10. DOI: 10.1007/978-3-319-74698-2_94-2.Peer-Reviewed Original ResearchConceptsTumor lysis syndromeWhite blood cell countDisseminated intravascular coagulationPeripheral blood white blood cell countBlood white blood cell countBiologically targeted therapiesHigher WBC countSupportive care measuresBlood cell countSymptomatic hyperleukocytosisSymptomatic leukostasisMalignant cloneCoagulation abnormalitiesDiagnostic workupIntravascular coagulationTargeted therapyLethal complicationPoor prognosisAggressive natureWBC countHyperleukocytosisAvoidable complicationsCell countPatient outcomesComplications
2025
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas
Mirza A, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Abid M, Afrough A, Ahmed S, Badar T, Barba P, Bhatt V, Brown V, Dahiya S, Deol A, Epperla N, Ganguly S, Grover N, Hashmi H, Hashmi S, Hematti P, Hildebrandt G, Hill J, Hossain N, Ibrahim U, Johnson P, Kharfan-Dabaja M, Krem M, Lekakis L, Maziarz R, Murthy H, Riedell P, Salas M, Shouse G, Strouse C, Thakar M, Turtle C, Woolfrey A, Wudhikarn K, Yared J, Pasquini M, Gowda L. Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas. Blood Neoplasia 2025, 3: 100187. PMID: 41867486, PMCID: PMC12999346, DOI: 10.1016/j.bneo.2025.100187.Peer-Reviewed Original ResearchCitationsAltmetricConceptsImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeRates of cytokine release syndromeCAR-T cell therapyLarge B-cell lymphomaB-cell lymphomaCD19-directed chimeric antigen receptor T cellsCD19 CAR T-cell therapyChimeric antigen receptor T cellsDiffuse large B-cell lymphomaSeverity of cytokine release syndromeCD19 CAR-T therapyToxicity outcomesOlder ageOutcomes of older patientsT-cell therapyCAR-T therapyAge groupsContinuous variablesAxicabtagene ciloleucelCAR-TRelapse rateRelapse riskT cellsPatient selectionInfection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Wudhikarn K, Herr M, Chen M, Martens M, Baird J, Gowda L, Rangarajan H, Abid M, Kharfan-Dabaja M, Williams K, Ganguly S, Young J, Sharma A, Fatobene G, Jain T, Kanakry C, Modi D, Grover N, Salem B, Batista M, Vergidis P, Yin D, Beitinjaneh A, Kelkar A, Nishihori T, Chakrabarty J, Gergis U, Smith M, Boghdadly Z, Dandoy C, Murthy H, Huppler A, Perales M, Chemaly R, Hill J, Riches M, Auletta J. Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Advances 2025, 9: 5460-5472. PMID: 40435511, PMCID: PMC12607006, DOI: 10.1182/bloodadvances.2025016141.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCD19 chimeric antigen receptorT-cell therapyCD19 chimeric antigen receptor T-cell therapyInfection-related mortalityCD19 CAR-T cellsCAR-T cellsT cellsSevere immune effector cell-associated neurotoxicity syndromeChimeric antigen receptor T-cell therapyImmune effector cell-associated neurotoxicity syndromeCD19 CAR T-cell therapyCAR-T cell therapySevere cytokine release syndromeRisk factorsChimeric antigen receptorInferior overall survivalMedian Follow-UpB-cell lymphomaCytokine release syndromeIndependent risk factorCause of morbidityDays post-infusionIncidence of infectionOutcome of infectionIncreased infection riskCost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML
Alhajahjeh A, Patel K, Podoltsev N, Kewan T, Stempel J, Mendez L, Seropian S, Gowda L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML. Blood Advances 2025, 9: 5234-5246. PMID: 40720773, PMCID: PMC12550792, DOI: 10.1182/bloodadvances.2025016532.Peer-Reviewed Original ResearchCitationsAltmetricConceptsUpfront hematopoietic stem cell transplantationHematopoietic stem cell transplantationIncremental net monetary benefitAllogeneic hematopoietic stem cell transplantationAcute myeloid leukemiaDisease-free survivalStem cell transplantationQuality-adjusted life yearsConsolidation chemotherapyOverall survivalCell transplantationIntermediate-risk acute myeloid leukemiaIntermediate-risk AML patientsIntermediate risk acute myeloid leukemiaNet monetary benefitCost-effective strategyHealth economic implicationsProbabilistic sensitivity analysesDeterministic sensitivity analysisSalvage treatmentAML patientsMyeloid leukemiaMonetary benefitsWTP thresholdPrimary outcomeAcute Toxicities of Bone Marrow Donation in Unrelated Donors with Sickle Cell Trait: A Center for International Blood and Marrow Transplantation Research Analysis
Farhadfar N, Bo-Subait S, Schmidt G, Logan B, Aljurf M, Badawy S, Beitinjaneh A, Gowda L, Kasow K, Seftel M, Sharma A, Rangarajan H, Herr M, Battiwalla M, Shaw B, Stefanski H. Acute Toxicities of Bone Marrow Donation in Unrelated Donors with Sickle Cell Trait: A Center for International Blood and Marrow Transplantation Research Analysis. Transplantation And Cellular Therapy 2025, 32: 217.e1-217.e12. PMID: 41072772, PMCID: PMC13051645, DOI: 10.1016/j.jtct.2025.10.007.Peer-Reviewed Original ResearchConceptsNational Marrow Donor ProgramSickle cell traitBM donorsBM donationUnrelated donorSkeletal painBone marrowGrade 2Allogeneic stem cell transplantationIncidence of grade 2Rate of persistent painLow riskRisk of perioperative mortalityGrade 1 painInternational donor registriesStem cell transplantationProbability of complete recoveryImpact of STMonths postdonationCell traitKaplan-Meier estimatesEthnic minority donorsLikelihood of participationLogistic regression modelsAcute toxicityAllogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study
Ustun C, Zhang M, Peterson A, Baek A, Agha M, Alkhateeb H, Chhabra S, Coltoff A, de Lima M, Gandhi A, Ho V, Kassim A, Lin A, Gowda L, Borthakur G, DeAngelo D, McGuirk J, Mensah F, Nadiminti K, Nishihori T, Pantin J, Trunk A, Uberti J, Marcucci G, Gotlib J, Akin C, Hamadani M, Pullarkat V, Valent P, Grunwald M, Juckett M, Oran B, Saber W, Burns L. Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study. British Journal Of Haematology 2025, 207: 2486-2495. PMID: 40983528, PMCID: PMC12519450, DOI: 10.1111/bjh.70154.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalPost-transplantation cyclophosphamideAdvanced systemic mastocytosisSystemic mastocytosisYear post-alloHCTOverall survivalKIT inhibitorsCumulative incidencePost-alloHCTBone marrow mast cell burdenCumulative incidence of relapse/progressionAllogeneic haematopoietic cell transplantationIncidence of relapse/progressionNon-myeloablative regimensPeripheral blood graftsMast cell burdenHaematopoietic cell transplantationOutcomes of patientsPopulation of patientsSM-AHNBlood graftsKIT mutationsCell transplantationHaematological neoplasmsSerum tryptaseStandard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
Sidana S, Ahmed N, Akhtar O, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Landau H, Mirza A, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini M. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood 2025, 146: 167-177. PMID: 40198886, PMCID: PMC12964216, DOI: 10.1182/blood.2024026216.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCAR-T cell therapyStandard of careIde-celComplete responseIdecabtagene vicleucelMultiple myelomaImmune effector cell-associated neurotoxicity syndromeClinical trialsMedian progression-free survivalHigh-risk cytogeneticsProgression-free survivalT-cell therapyTreatment-related mortalityRelapsed/Refractory Multiple MyelomaMedian Follow-UpClinically significant infectionsCytokine release syndromeSignificant co-morbiditiesSignificant co-morbidityEffects of standard of careExtramedullary diseaseCAR-TMyeloid malignanciesPrimary malignancyMedian ageImpact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant
VanOudenhove J, Liu Y, Nelakanti R, Kim D, Busarello E, Ovalle N, Qi Z, Mamillapalli P, Siddon A, Bai Z, Axtmayer A, Corso C, Kothari S, Foss F, Isufi I, Tebaldi T, Gowda L, Fan R, Seropian S, Halene S. Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant. PLOS ONE 2025, 20: e0320744. PMID: 40294012, PMCID: PMC12036906, DOI: 10.1371/journal.pone.0320744.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsHematopoietic stem cell transplantationMemory T cellsStem cell transplantationCell transplantationT cellsSARS-CoV-2Hematopoietic stem cell transplant recipientsAntigen-specific T-cell activationSARS-CoV-2 mRNA vaccinesSARS-CoV-2 vaccine responsesSevere diseaseAnti-spike IgGT cell activationAdaptive immune responsesRobust antibody responsesPost-vaccination responseSARS-CoV-2 infectionMRNA vaccine seriesSingle-cell RNAMyeloablative chemotherapyCellular responsesImmune profileVaccine responseCOVID-19 infectionMRNA vaccinesTeduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey
Brehm N, Biavasco F, Clausen J, Jung J, Maas-Bauer K, Wäsch R, Verbeek M, Nuernbergk C, Ihorst G, Seropian S, Finke J, Gowda L, Sidlik Muskatel R, Peffault de Latour R, Socie G, Wehr C, Michonneau D, Zeiser R. Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. Bone Marrow Transplantation 2025, 60: 873-878. PMID: 40229535, PMCID: PMC12151853, DOI: 10.1038/s41409-025-02586-2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGlucagon-like peptide-2Non-relapse mortalityIntestinal acute graft-versus-host diseaseLevels of glucagon-like peptide-2Acute graft-versus-host diseaseGraft-versus-host diseaseMulticenter surveyAllogeneic hematopoietic cell transplantationRetrospective multicenter surveyHematopoietic cell transplantationFraction of patientsAlbumin serum levelsIntestinal stem cellsGVHD severitySR-aGVHDTeduglutide treatmentAcute GVHDAllo-HCTCell transplantationProspective trialsPreclinical dataSerum levelsTreated patientsRetrospective analysisFollow-up
Clinical Trials
Current Trials
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
IRB ID2000029882RoleSub InvestigatorPrimary Completion Date11/30/2036Recruiting ParticipantsA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
IRB ID2000028478RoleSub InvestigatorPrimary Completion Date07/30/2023Recruiting ParticipantsManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
IRB ID2000025634RoleSub InvestigatorPrimary Completion Date07/06/2023Recruiting Participants
Academic Achievements & Community Involvement
Copy Link
Activities
activity American Society of Oncology
2011 - PresentProfessional OrganizationsMemberactivity American Society of Hematology
2011 - PresentProfessional OrganizationsMemberactivity Yale Stem Cell Transplant QI Committee
2018 - PresentProfessional OrganizationsMemberactivity YCC Data Safety Monitoring Committee
2019 - PresentProfessional OrganizationsMemberactivity American Society for Blood and Marrow Transplantation
2017 - PresentProfessional OrganizationsMember
Honors
honor DAVID S FISHER Annual Award
06/14/2023Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor American Society of Hematlogy Abstract Achievement Award
10/02/2017National AwardDetailsUnited Stateshonor Academy of Clinical Laboratory Physicians and Scientists-Paul E. Strandjord Young Investigator Award
12/01/2016National AwardDetailsUnited Stateshonor American Association of Blood Banks-Fenwal Scholarship
12/01/2015National AwardDetailsUnited Stateshonor Drexel Discovery Day Research Award
09/30/2009Regional AwardDrexel University College of MedicineDetailsUnited States
Clinical Care
Copy Link
Overview
Lohith Gowda, MD, is a hematologist, which means he studies and treats blood-based diseases and cancers including leukemia and bone marrow failure.
Dr. Gowda’s team includes not just other doctors and scientists but patients and their families. The team meets often to help patients and families navigate the complexities of stem-cell transplant and cellular therapy, all of which are involved in the treatment of blood-based diseases. It is important for patients and families to fully understand options for care in order to make informed decisions, he says.
An active researcher, Dr. Gowda’s work examines the effectiveness of specific strategies for treating blood disorders, as well as their effects on patients’ well-being and long-term care. While transplantation may give patients a new lease on life, dedicated follow-up care for transplant recipients is vital, Dr. Gowda says.
Dr. Gowda is a member of the Royal College of Physicians and has received many awards, including the Young Investigator Award from the Academy of Clinical Laboratory Physicians and Scientists and the American Society of Hematology’s Abstract Achievement Award.
Clinical Specialties
Hematology
Fact Sheets
Acute Myeloid Leukemia (AML)
Learn More on Yale MedicineCAR T-Cell Therapy
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale MedicineMyelodysplastic/Myeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- December 15, 2025
Yale Department of Internal Medicine Faculty Promotions and Appointments (December 2025)
- March 25, 2024
Yale’s Post ASH Review
- November 28, 2023
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Get In Touch
Copy Link
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.